Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRAX 
Praxis Precision Medicines Inc (PRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PRAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $101.31
1 Year Target Price $101.31
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.53% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 793.68M USD | Price to earnings Ratio - | 1Y Target Price 101.31 |
Price to earnings Ratio - | 1Y Target Price 101.31 | ||
Volume (30-day avg) 12 | Beta 2.62 | 52 Weeks Range 26.70 - 91.83 | Updated Date 09/15/2025 |
52 Weeks Range 26.70 - 91.83 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3497.57% |
Management Effectiveness
Return on Assets (TTM) -37.98% | Return on Equity (TTM) -60.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 493154602 | Price to Sales(TTM) 102.21 |
Enterprise Value 493154602 | Price to Sales(TTM) 102.21 | ||
Enterprise Value to Revenue 63.51 | Enterprise Value to EBITDA -6.86 | Shares Outstanding 21049600 | Shares Floating 15645644 |
Shares Outstanding 21049600 | Shares Floating 15645644 | ||
Percent Insiders 0.15 | Percent Institutions 113.12 |
Upturn AI SWOT
Praxis Precision Medicines Inc
Company Overview
History and Background
Praxis Precision Medicines, Inc. is a biopharmaceutical company founded in 2015. It focuses on developing therapies for central nervous system (CNS) disorders. Key milestones include identifying promising drug candidates and advancing them through clinical trials. The company has transitioned from early-stage research to a clinical-stage organization.
Core Business Areas
- CNS Therapies Development: Focused on creating treatments for neurological and psychiatric disorders.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Precision Medicines: Developing therapies tailored to specific patient populations based on genetic and other biomarkers.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure includes departments for research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- PRAX-944: An investigational T-type calcium channel blocker under development for essential tremor. Market share is currently zero as it is not yet approved. Key competitors in this area include existing treatments and other companies developing novel therapies for tremor.
- PRAX-562: An investigational compound for epilepsy and other neurological disorders. Market share is currently zero as it is not yet approved. Key competitors in this area include existing anti-epileptic drugs and other companies developing novel therapies for epilepsy.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically the segment focused on CNS disorders, is characterized by high research and development costs, lengthy regulatory approval processes, and significant unmet medical needs. The industry is driven by innovation and the development of novel therapies.
Positioning
Praxis Precision Medicines is positioned as a precision medicine company focused on developing therapies for CNS disorders. Its competitive advantage lies in its focus on identifying specific patient populations and developing therapies tailored to their needs.
Total Addressable Market (TAM)
The TAM for CNS therapies is substantial, estimated to be in the tens of billions of dollars annually. Praxis is positioned to capture a portion of this market with successful drug development and commercialization.
Upturn SWOT Analysis
Strengths
- Strong focus on precision medicine
- Experienced management team
- Proprietary technology platform
- Pipeline of promising drug candidates
Weaknesses
- Limited revenue as a clinical-stage company
- High dependence on clinical trial outcomes
- Reliance on external funding
- Competition from larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline through acquisitions or in-licensing
- Successful clinical trial results leading to regulatory approval
- Growing demand for personalized medicine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- EPIX
- LLY
- ABBV
Competitive Landscape
Praxis Precision Medicines faces competition from established pharmaceutical companies and other biotechnology companies developing therapies for CNS disorders. Its success depends on its ability to differentiate its therapies and demonstrate clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of drug candidates through preclinical and clinical development.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approval of its drug candidates.
Recent Initiatives: Recent initiatives include advancing PRAX-944 and PRAX-562 through clinical trials and exploring potential partnerships to expand the pipeline.
Summary
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision medicines for CNS disorders. The company's success hinges on the successful completion of clinical trials and regulatory approval of its drug candidates. They possess a solid pipeline, but face risks inherent in drug development. Praxis's future looks bright, but challenges in obtaining funding and competition loom.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Praxis Precision Medicines Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-16 | President, CEO & Director Mr. Marcio Silva De'Souza M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://praxismedicines.com |
Full time employees 116 | Website https://praxismedicines.com | ||
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.